Nanomedical Diagnostics Launches New Graphene Biosensor for Validating Primary Screen Hits During Early Stage Drug Discovery

Tuesday, July 10, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

False positives are common when using labeled biochemical assays to measure high-concentration interactions. SCOOH Agile biosensors present a possible solution.

SAN DIEGO, July 10, 2018 /PRNewswire-PRWeb/ -- Nanomedical Diagnostics, leading manufacturer of graphene biosensors

that accelerate pharmaceutical development, launches the new Super Amine-Immobilization Biosensor – SCOOH, for use with the company's optics-free assay troubleshooting system, Agile R100. The new graphene biosensor allows for immobilization of targets onto the sensor surface via free amine groups and has 25 times the binding capacity of the existing COOH Agile biosensor.

"At Nanomedical Diagnostics, we strive to make the small molecule drug discovery process faster and less costly," says CEO Ross Bundy. "The new SCOOH Agile biosensor provides biochemists with an orthogonal option to quickly check hits from primary screens prior to sending them on to expensive, time-consuming secondary screening. With a direct measurement technique to confirm results available to all researchers, less time and fewer resources may be spent on compounds that ultimately fail."

The SCOOH Agile Biosensor is specifically designed for the high concentrations typically used in primary screens, with a hydrophilic surface that reduces nonspecific binding of hydrophobic compounds. Coated with a high density of binding sites for target attachment, the biosensor avoids saturation at high concentrations, enabling accurate results and reduced false positives. Like all Agile biosensors, the SCOOH sensor is undeterred by complex samples such as 10% DMSO and uses just a 10 µL drop of sample.

"The Agile R100 personal assay system is designed for small molecule drug discovery," continues Mr. Bundy. "The platform uses an electrical sensing mechanism called Field Effect Biosensing which is not dependent on optics or molecule mass. Small molecules produce large chemical potential shifts in relation to their volume, which in turn produces a large signal on the Agile R100 platform. Combined with the new SCOOH Agile biosensor which excels with high concentration measurements, pharmaceutical researchers now have an accurate quick-check method to verify positive hits on their timeline and in their control."

About Nanomedical Diagnostics

Nanomedical Diagnostics ("Nanomed") is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive label-free kinetic characterization of biomolecular interactions for accelerated drug discovery. As the world's leading developer and manufacturer of next-generation graphene biosensors, Nanomed's mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.

 

SOURCE Nanomedical Diagnostics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store